CAR T Cell/Ibrutinib Combination May Improve CLL Response Rates – Cancer Network
|
CAR T Cell/Ibrutinib Combination May Improve CLL Response Rates
Cancer Network Despite immune-related adverse events, concurrent ibrutinib and anti-CD19 chimeric antigen receptor (CAR) T-cell therapy may improve response rates in patients with chronic lymphocytic leukemia (CLL), according to early results (abstract 7509) from a … |
